Highlights
- CHM is set to present at the NWR Virtual Healthcare Conference.
- The company is committed to advancing cellular therapies for cancer treatment.
CHM 1101 (CLTX CAR T), CHM 2101 (CDH17 CAR T), and CHM 0201 (CORE-NK platform) are being studied for cancer treatment. Chimeric Therapeutics Limited (ASX: CHM) is scheduled to participate in the NWR Virtual Healthcare Conference. Jennifer Chow, CEO and MD will present the company’s clinical progress at the event on 20 March 2024.
CHM is an ASX-listed clinical-stage cell therapy company with a portfolio that includes autologous CAR T and allogeneic NK cell therapies. These assets are being developed for various disease areas in oncology.
Clinical programs:
CHM 1101 – It is a CAR T therapy currently in the Phase 1B clinical trial for progressive/ recurrent glioblastoma. The Phase 1 A clinical trial delivered promising preliminary results in October 2023. The Phase 1B trial has also progressed with the first patient being dosed in November 2023.
CHM 2101 – It is a third generation CDH17 CAR T focusing on gastrointestinal cancers. It has received IND clearance from the FDA. Currently, it is in preclinical development, and Phase 1A trial is planned.
CHM 0201 – It is an NK cell platform that completed Phase 1A clinical trial, demonstrating safety and efficacy in blood cancers and solid tumours. The company has initiated Phase 1B clinical trial to study CHM 0201 in combination with IL2 and Vactosertib.
CHM shares traded at AU$0.028 apiece at the time of writing on 15 March 2024.